Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 92. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis1609
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial1330
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database1163
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of obser902
476P How to predict microsatellite instability (MSI) status in locally advanced gastric cancer? A preoperative CT-based proposal774
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?680
215P Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors650
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors638
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort604
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity556
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)552
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis450
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer426
13P Genomic signatures of recurrence after resection of node-negative colorectal cancer425
Table of Contents410
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)396
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study387
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy382
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy336
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma328
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part316
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies313
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC299
1768P Desmoid tumors: Experience of a Spanish reference center299
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial270
2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials241
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making240
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival237
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer230
CN107 The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study222
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma213
568P Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort211
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study208
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)200
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)197
1493P The Italian version of the FAMCARE-P13 questionnaire: A validation study193
1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (N188
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (c184
1385P Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma182
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus180
Imatinib’s last lessons? A roadmap to cure177
495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junct177
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)175
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma172
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country172
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer172
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE168
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway160
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre159
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India158
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study156
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling150
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction144
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study142
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor139
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC134
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals134
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China132
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care124
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin124
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%122
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study121
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes121
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported 120
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma119
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer118
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report117
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era117
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia115
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis114
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience114
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients113
1242MO The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study113
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study113
1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling112
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment109
CN14 Cancer prevention awareness among Croatian AYA population108
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)108
82P Obtaining microvesicles from T-lymphocytes using various methods of induction107
332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study105
166P Metabolomic prediction of breast cancer treatment toxicities105
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes103
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi101
2335P Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma101
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study100
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)96
1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites94
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy93
1905P Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma93
2092P Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors93
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study92
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)92
0.39544796943665